Seeking Alpha
24 Jul 2026, 13:45 UTC · 16w ago
Legend Biotech: Why I'm Ready To Go Long Again
Impact · against what's priced in
Strong Q2 sales growth for Carvykti provide a positive catalyst for LEGN and JNJ, likely leading to an earnings beat for Legend Biotech. The sequential and year-on-year revenue increases signal sustained market penetration for the CAR-T therapy.
- LEGN+0.80
No priced-in read yet
- In context
The combination of 10.1% quarter-on-quarter growth and $657 million in total Q2 sales suggests the company is positioned to beat consensus estimates.
Read from the article alone

Top 1 mover · tap to explore




